title: Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
abstract: BACKGROUND
  The aim of this work was to investigate if serum and salivary auto-antibodies, isotypes IgG and IgM, against HER2 and MUC1 tandem repeat fragments could play a role in breast cancer screening.
  
  
  METHODS
  Our case-control study was conducted in breast cancer patients, in early stages (n=29), at the gynecology service, Maternity Souissi Hospital, Rabat, Morocco and healthy woman (n=31). Salivary and serum auto-antibodies against HER2 and MUC1 (tandem repeat) were assessed by enzyme-linked immunosorbent assay (ELISA) and compared between patients and healthy women using the Mann-Whitney U test. A P-value <0.05 was considered to be statistically significant.
  
  
  RESULTS
  Our data showed higher expression of all serum and salivary autoantibodies in patients as compared to healthy women p<0.05. However, serum IgM anti-MUC1 expression did not show a significant difference between cases and controls (p=0.79). Similarly, salivary IgG anti-HER2 expression did not differ (p=0.15). The correlation between the different isotypes of antibodies revealed that the highest correlation was between salivary IgG anti-HER2 and salivary IgG anti- MUC1(r=0.65). In fact, we have found in saliva the correlation between autoantibodies anti-MUC1 and anti-HER2 more important than in serum (r=0.59 and r=0. 55). However, the correlation between serum and saliva values for all antibodies was weak.
  
  
  CONCLUSIONS
  Autoantibodies against HER2 and MUC1 may provide a useful approach in breast cancer screening when using both serum and saliva values.
authors.affiliation: Oral Biomechanics and Biotechnology Research Unit, Faculty of Dental Medicine, University Mohammed V, Rabat, Morocco E-mail : laidi.fatna@gmail.com.
authors.forename: Fatna
authors.initials: F
authors.lastname: Laidi
authors.forename: Amal
authors.initials: A
authors.lastname: Bouziane
authors.forename: Abdelhamid
authors.initials: A
authors.lastname: Errachid
authors.forename: Fatima
authors.initials: F
authors.lastname: Zaoui
mesh_terms: D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology; D016022:Case-Control Studies; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D008875:Middle Aged; D018396:Mucin-1 / Q000276:immunology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D012463:Saliva / Q000276:immunology*; D044967:Serum / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D018396:Mucin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; C060192:MUC1 protein, human; C508053:ERBB2 protein, human